| Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae … RK Shields, L Chen, S Cheng, KD Chavda, EG Press, A Snyder, ... Antimicrobial agents and chemotherapy 61 (3), 10.1128/aac. 02097-16, 2017 | 503 | 2017 |
| Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia RK Shields, MH Nguyen, L Chen, EG Press, BA Potoski, RV Marini, Y Doi, ... Antimicrobial agents and chemotherapy 61 (8), 10.1128/aac. 00883-17, 2017 | 491 | 2017 |
| Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance ZA Qureshi, LE Hittle, JA O'Hara, JI Rivera, A Syed, RK Shields, ... Clinical infectious diseases 60 (9), 1295-1303, 2015 | 462 | 2015 |
| Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections RK Shields, BA Potoski, G Haidar, B Hao, Y Doi, L Chen, EG Press, ... Clinical Infectious Diseases 63 (12), 1615-1618, 2016 | 455 | 2016 |
| Performance of Candida Real-time Polymerase Chain Reaction, β-D-Glucan Assay, and Blood Cultures in the Diagnosis of Invasive Candidiasis MH Nguyen, MC Wissel, RK Shields, MA Salomoni, B Hao, EG Press, ... Clinical infectious diseases 54 (9), 1240-1248, 2012 | 344 | 2012 |
| Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae … RK Shields, MH Nguyen, L Chen, EG Press, BN Kreiswirth, CJ Clancy Antimicrobial agents and chemotherapy 62 (5), 10.1128/aac. 02497-17, 2018 | 271 | 2018 |
| Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance G Haidar, NJ Philips, RK Shields, D Snyder, S Cheng, BA Potoski, Y Doi, ... Clinical Infectious Diseases 65 (1), 110-120, 2017 | 267 | 2017 |
| Mutations in blaKPC-3 That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-Lactamases G Haidar, CJ Clancy, RK Shields, B Hao, S Cheng, MH Nguyen Antimicrobial agents and chemotherapy 61 (5), 10.1128/aac. 02534-16, 2017 | 195 | 2017 |
| The Presence of an FKS Mutation Rather than MIC Is an Independent Risk Factor for Failure of Echinocandin Therapy among Patients with Invasive Candidiasis … RK Shields, MH Nguyen, EG Press, AL Kwa, S Cheng, C Du, CJ Clancy Antimicrobial agents and chemotherapy 56 (9), 4862-4869, 2012 | 187 | 2012 |
| Comparison of an Aspergillus Real-time Polymerase Chain Reaction Assay With Galactomannan Testing of Bronchoalvelolar Lavage Fluid for the Diagnosis of … ML Luong, CJ Clancy, A Vadnerkar, EJ Kwak, FP Silveira, MC Wissel, ... Clinical Infectious Diseases 52 (10), 1218-1226, 2011 | 162 | 2011 |
| Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients RK Shields, CJ Clancy, LM Gillis, EJ Kwak, FP Silveira, RCA Massih, ... PloS one 7 (12), e52349, 2012 | 160 | 2012 |
| Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents R Almaghrabi, CJ Clancy, Y Doi, B Hao, L Chen, RK Shields, EG Press, ... Antimicrobial agents and chemotherapy 58 (8), 4443-4451, 2014 | 156 | 2014 |
| Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and … D Mitsani, MH Nguyen, RK Shields, Y Toyoda, EJ Kwak, FP Silveira, ... Antimicrobial agents and chemotherapy 56 (5), 2371-2377, 2012 | 152 | 2012 |
| Intra-abdominal candidiasis: the importance of early source control and antifungal treatment P Vergidis, CJ Clancy, RK Shields, SY Park, BN Wildfeuer, RL Simmons, ... PLoS One 11 (4), e0153247, 2016 | 148 | 2016 |
| Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae G Haidar, CJ Clancy, L Chen, P Samanta, RK Shields, BN Kreiswirth, ... Antimicrobial agents and chemotherapy 61 (9), 10.1128/aac. 00642-17, 2017 | 142 | 2017 |
| Effects of Klebsiella pneumoniae Carbapenemase Subtypes, Extended-Spectrum β-Lactamases, and Porin Mutations on the In Vitro Activity of Ceftazidime … RK Shields, CJ Clancy, B Hao, L Chen, EG Press, NM Iovine, ... Antimicrobial agents and chemotherapy 59 (9), 5793-5797, 2015 | 140 | 2015 |
| Carbapenem-resistant Pseudomonas aeruginosa bacteremia: risk factors for mortality and microbiologic treatment failure DJ Buehrle, RK Shields, LG Clarke, BA Potoski, CJ Clancy, MH Nguyen Antimicrobial agents and chemotherapy 61 (1), 10.1128/aac. 01243-16, 2017 | 135 | 2017 |
| Emergence of ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in Klebsiella pneumoniae carbapenemase-producing K pneumoniae: a case report and … RK Shields, MH Nguyen, EG Press, L Chen, BN Kreiswirth, CJ Clancy Open Forum Infectious Diseases 4 (3), ofx101, 2017 | 126 | 2017 |
| Abdominal candidiasis is a hidden reservoir of echinocandin resistance RK Shields, MH Nguyen, EG Press, CJ Clancy Antimicrobial agents and chemotherapy 58 (12), 7601-7605, 2014 | 123 | 2014 |
| Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure RK Shields, MH Nguyen, EG Press, CL Updike, CJ Clancy Antimicrobial agents and chemotherapy 57 (8), 3528-3535, 2013 | 116 | 2013 |
